This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antigenics Reports Third Quarter 2010 Financial Results

LEXINGTON, Mass., Oct. 28, 2010 (GLOBE NEWSWIRE) -- Antigenics Inc. (Nasdaq:AGEN) reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009. For the nine months ended September 30, 2010, the company incurred a net loss attributable to common stockholders of $20.1 million, or $0.21 per share, basic and diluted, compared with a net loss attributable to common stockholders of $32.8 million, or $0.43 per share, basic and diluted, for the comparable period in 2009. The company's net cash burn (cash used in operating activities plus capital expenditures and dividend payments) for the three months ended September 30, 2010 and 2009 was $4.4 million and $5.8 million, respectively. The company's net cash burn for the nine months ended September 30, 2010 and 2009 was $14.0 million and $21.3 million, respectively. The 2010 results primarily reflect the company's continuing support of Oncophage® vaccine as well as its cost containment efforts. Cash, cash equivalents, and short-term investments were $24.4 million as of September 30, 2010.

Corporate Update
  • GlaxoSmithKline recently initiated a Phase 3 clinical program testing a vaccine containing Antigenics' QS-21 Stimulon® immune adjuvant for the prevention of shingles. With the initiation of this program, there are now four QS-21-containing vaccines currently being tested in Phase 3 clinical trials. The first products containing QS-21 are expected to be launched in 2013/2014. Additional Phase 3 programs include vaccines for malaria, melanoma and non-small cell lung cancer. Antigenics is entitled to milestone payments as these programs advance, as well as royalties for at least 10 years after commercial launch. The cost of developing and marketing these vaccines is assumed by the company's licensees.
  • Recent Phase 1 data for AG-707, our therapeutic vaccine candidate, showed that 100% of evaluable patients receiving AG-707 with QS-21 demonstrated a statistically significant CD4+ T-cell response to HSV-2 antigens, and a majority of those patients (63%) demonstrated a CD8+ T-cell response. Eliciting both of these types of immune responses is a first of its kind achievement in herpes therapy. We are currently seeking partners for the further development of AG-707.
  • Enrollment continues in two Phase 2 clinical trials testing Oncophage® vaccine in recurrent and newly diagnosed glioma, or brain cancer. The trials are being led by Dr. Andrew Parsa of the University of California, San Francisco (UCSF) and are supported with funding from American Brain Tumor Association, Accelerated Brain Cancer Cure, National Brain Tumor Society, and the National Cancer Institute Special Programs of Research Excellence. Data from the first 32 recurrent glioma patients showed median survival of 44 weeks compared with a historical median of 26 weeks. All patients tested exhibited a significant generalized innate immune response, and 92% showed an adaptive tumor-antigen specific immune response demonstrated by a significant increase in CD4+ and CD8+ T-cell responses.
  • A second glioma trial has been underway in newly diagnosed patients. This trial involves the administration of Oncophage in combination with radiation and Temodar (Merck; temozolomide). Based on encouraging early results from this trial, it is now expanding to include over 9 leading brain tumor research centers in the United States.
  • Antigenics is collaborating with UCSF on the design and execution of a Phase 1 trial testing Oncophage in pediatric brain tumors.
  • The company continues to explore development and commercial partnerships for Oncophage on both a global and regional basis in both renal cell carcinoma (RCC; kidney cancer) and glioma.
  • Antigenics is pursuing several collaborations to test Oncophage in combination with other investigational and/or commercially available therapies that may work synergistically to improve the efficacy of Oncophage in late stage cancers.

Conference Call Information

Antigenics executives will host a conference call at 11:00 a.m. Eastern Time today. To access the live call, dial 877.475.3568 (domestic) or 678.809.3092 (international); the access code is 18732304. The call will also be webcast and will be accessible from the company's website at . A replay will be available approximately two hours after the call through midnight Eastern Time on March 28, 2011. The replay number is 800.642.1687 (domestic) or 706.645.9291 (international), and the access code is 18732304. The replay will also be available on the company's website approximately two hours after the live call.

About Antigenics

Antigenics is a biotechnology company working to develop treatments for cancers and infectious diseases. For more information, please visit .

The Antigenics Inc. logo is available at

This earnings release contains forward-looking statements, including statements regarding development, commercialization and partnering efforts; clinical trial activities; data, results and timelines of the company and its licensees and collaborators; and the cash position of the company. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, decisions by regulatory authorities, physicians patients, and our existing and potential licensees and collaborators; the possibility that clinical trial results will not be favorable; the inability to secure local distributors, service providers, and payment mechanisms in Russia; the inability to secure favorable partnering arrangements; the ability to raise capital and finance future activities and maintain our listing on the NASDAQ Capital Market; Antigenics' dependence on its collaborative partners to successfully develop and commercialize products; and the factors described under the Risk Factors section of our Annual Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended June 30, 2010. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.
Summary Consolidated Financial Information
Condensed Consolidated Statements of Operations Data
  Three months ended September 30, Nine months ended September 30,
  2010 2009 2010 2009
Revenue  $ 624  $ 896  $ 2,366  $ 2,787
Operating expenses:        
Cost of sales  65  --   123  -- 
Research and development  2,822  3,747  10,082  13,680
General and administrative   2,624  3,515  8,958  11,589
Operating loss  (4,887)  (6,366)  (16,797)  (22,482)
Other expense, net  820  4,246  2,693  9,695
Net loss  (5,707)  (10,612)  (19,490)  (32,177)
Dividends on Series A convertible preferred stock  (198)  (198)  (593)  (593)
Net loss attributable to common stockholders  $ (5,905)  $ (10,810)  $ (20,083)  $ (32,770)
Per common share data, basic and diluted:      
Net loss attributable to common stockholders  $ (0.06)  $ (0.13)  $ (0.21)  $ (0.43)
Weighted average number of common shares outstanding, basic and diluted  99,097  85,802  95,307  75,335
Condensed Consolidated Balance Sheet Data
(in thousands)
  September 30, 2010 December 31, 2009    
Cash, cash equivalents, and short-term investments  $ 24,404  $ 30,065    
Total assets  36,616  45,874    
Total stockholders' deficit  (25,080)  (16,975)    
CONTACT:  Antigenics Inc.
          Shalini Sharp

company logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,636.79 +164.42 1.00%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs